Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis Ran Chen, Pei-Chun Peng, Bin Wen, Fu-Ying.

Slides:

Advertisements

Similar presentations

A High-Density SNP Genotyping Array for Rice Biology and Molecular Breeding Haodong Chen, Weibo Xie, Hang He, Huihui Yu, Wei Chen, Jing Li, Renbo Yu, Yue.

Advertisements

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease- Free Survival of Glioblastoma Patients Jie Xu, Zhaoli Li, Jilin Wang,

A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic.

miR p Is a Novel Prognostic Biomarker of Prostate Cancer

Anticoagulation Regimens During Pregnancy in Patients With Mechanical Heart Valves: A Systematic Review and Meta-analysis Zhe Xu, MD, PhD, Jin Fan, MD,

Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced.

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

Educational intervention on physical restraint use in long-term care facilities – Systematic review and meta-analysis Shao-Huan Lan, Li-Chin Lu, Shou-Jen.

Volume 36, Issue 3, Pages (June 2017)

Colistin for the treatment of ventilator-associated pneumonia caused by multidrug- resistant Gram-negative bacteria: A systematic review and meta-analysis

Volume 64, Pages e1-e3 (January 2017)

Laparoscopic Versus Open Radical Nephrectomy for Renal Cell Carcinoma: a Systematic Review and Meta-Analysis Gang Liu, Yulei Ma, Shouhua Wang, Xiancheng.

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: A meta- analysis Yin-Xi Zhang, Chun-Hong Shen, Qi-Lun Lai, Gao-Li Fang, Wen-Jie.

Multiple-dose and double-dose versus single-dose administration of methotrexate for the treatment of ectopic pregnancy: a systematic review and meta-analysis

Paravertebral block in paediatric abdominal surgery'a systematic review and meta- analysis of randomized trials E.A. Page, K.L. Taylor British Journal.

The importance of dose in land-based supervised exercise for people with hip osteoarthritis. A systematic review and meta-analysis T. Moseng, H. Dagfinrud,

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing Klazien Matter-Walstra, PhD, Matthias.

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Ming-quan Huang, Mou Li, Jing-yu Mao, Bo-le Tian

Can Imaging Parameters Provide Information Regarding Histopathology in Head and Neck Squamous Cell Carcinoma? A Meta-Analysis Alexey Surov, Hans Jonas.

Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With.

Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT Zhen-Yu He, San-Gang Wu, Fang Peng,

Preoperative Nutritional Deficiency Is a Useful Predictor of Postoperative Outcome in Patients Undergoing Curative Resection for Gastric Cancer Xuechao.

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome Alexandria D. Taylor,

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

International Journal of Surgery

A. Osman, J. Pundir, M. Elsherbini, S. Dave, T. El-Toukhy, Y. Khalaf

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract Ji Yun Lee, Kyung Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong.

Volume 146, Issue 3, Pages (September 2017)

Comparison of EUS with MRCP in idiopathic acute pancreatitis: a systematic review and meta-analysis Jianhua Wan, MD, Yaobin Ouyang, MD, Chen Yu, MD,

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Topical Analgesics in the Management of Acute and Chronic Pain

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Effect of combining tramadol and morphine in adult surgical patients: a systematic review and meta-analysis of randomized trials V. Martinez, L. Guichard,

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen–Mismatched Stem Cell Microtransplantation Improved Outcomes.

Targeting T Cell Co-receptors for Cancer Therapy

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Volume 127, Issue 6, Pages (December 2004)

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Volume 393, Issue 10172, Pages (February 2019)

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Distribution of Measured GFR in Apparently Healthy Chinese Adults

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

Dose-per-Fraction Escalation of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Volume 152, Issue 1, Pages (January 2019)

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Yu-Chen Huang, MD, Ying-Chih Cheng, MD

Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma Qingyuan.

A systematic review and meta-analysis of the comparison of performance among step- tip, split-tip, and symmetrical-tip hemodialysis catheters Xiao-Chun.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Anti–Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis Ran Chen, Pei-Chun Peng, Bin Wen, Fu-Ying Li, Sheng Xie, Guozhong Chen, Jiefu Lu, Zhuoyu Peng, Shao-Bo Tang, Yu-Mei Liang, Xin Deng Translational Oncology Volume 9, Issue 1, Pages 32-40 (February 2016) DOI: 10.1016/j.tranon.2015.11.010 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Flowchart representing the systematic identification of studies. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 2 Assessment of risk bias. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 3 Forest plot depicting the overall response rate of nivolumab compared with chemotherapy. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 4 Forest plot depicting the comparison of adverse events associated with nivolumab and chemotherapy. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 5 Forest plot depicting the 1-year OS rates of nivolumab and dacarbazine. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 6 Forest plot depicting the PFS rates associated with nivolumab and dacarbazine. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 7 Forest plot depicting the objective response rates associated with nivolumab and dacarbazine. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 8 Forest plot depicting the comparison of adverse events associated with nivolumab and dacarbazine. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 9 Forest plot depicting the overall response rate with different doses (2 and 10 mg/kg) of pembrolizumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 10 Forest plot depicting the PFS rates associated with different doses (2 and 10 mg/kg) of pembrolizumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 11 Forest plot depicting 1-year survival rates associated with different doses (2 and 10 mg/kg) of pembrolizumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 12 Forest plot depicting overall response rates of different doses (0.3 and 2 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 13 Forest plot depicting the PFS rates associated with different doses (0.3 and 2 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 14 Forest plot depicting the OS rates associated with different doses (0.3 and 2 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 15 Forest plot depicting the overall response rates associated with different doses (0.3 and 10 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 16 Forest plot depicting PFS rates associated with different doses (0.3 and 10 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 17 Forest plot depicting the OS rates associated with different doses (0.3 and 10 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 18 Forest plot depicting the overall response rates associated with different doses (2 and 10 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 19 Forest plot depicting the OS rates associated with different doses (2 and 10 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions

Figure 20 Forest plot depicting the PFS rates associated with different doses (2 and 10 mg/kg) of nivolumab. Translational Oncology 2016 9, 32-40DOI: (10.1016/j.tranon.2015.11.010) Copyright © 2016 The Authors Terms and Conditions